ERBB2 and breast carcinoma: However, in Lewis et al.'s (2011) study, the GCDFP-15 expression rate in ductal breast cancer was 65-71%, in HER2-positive breast carcinoma was 64%, and in TNBC breast carcinoma was 3% (26).